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Mismatch repair (MMR) deficiency in tumours from patients with the hereditary nonpolyposis colorectal cancer (HNPCC) syndrome
is mainly caused by mutations in the MLH1, MSH2, and MSH6 genes. A major challenge in the clinical management of patients with
suspected HNPCC is the frequent occurrence of missense mutations in MSH6. These can be considered neither deleterious nor
clinically innocent a priori. To assess their significance we studied five novel MSH6 missense mutations in six patients derived from a
series of consecutive endometrial and colorectal cancer patients selected for study after their tumours were determined to be
microsatellite unstable. We tested each mutated protein for heterodimerisation with MSH2 and for in vitro MMR capability. Four
mutations (R128L, P623L, K728T, G881KþS) showed no impairment of these functions while the fifth (E1193K) displayed marked
impairment of both functions. These results, taken together with our previous similar findings concerning six other missense
mutations in MSH6, allow us to conclude that many or most missense changes in MSH6 likely are clinically innocent, whereas some
missense changes such as E1193K, which lead to impaired MMR, are likely to be clinically significant, but have low penetrance.
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The cancer susceptibility in hereditary nonpolyposis colorectal
cancer (HNPCC) syndrome is associated with defective DNA
mismatch repair (MMR). An inherited defect in one MMR allele
and an acquired defect in the other allele lead to loss of MMR
function in the respective polypeptide that accelerates tumour
progression. Accordingly, lack of the mutated protein and
instability at short tandem repeat sequences such as microsatellites
in the genome are the main molecular characteristics of the
HNPCC tumours.
More than 450 different MMR gene mutations and 100
intragenic polymorphisms, affecting mostly the MMR genes,
MLH1, MSH2, and MSH6, are listed in the international HNPCC
mutation database (http://www.nfdht.nl). The clinical phenotype
varies between families. Contrary to most mutations affecting the
MLH1 and MSH2 genes, a significant proportion of MSH6
mutations occur in HNPCC families with less typical clinical
features. Carriers of MSH6 mutations often display late age at
onset, carcinomas of the endometrium, and low or no micro-
satellite instability (MSI) in tumours (Miyaki et al, 1997; Kolodner
et al, 1999; Wijnen et al, 1999; Wu et al, 1999; Parc et al, 2000;
Wagner et al, 2001; Berends et al, 2002; Peterlongo et al, 2003;
Cederquist et al, 2004). Moreover, one-third of MSH6 mutations
are nontruncating, and so do not necessarily destroy the encoded
protein. These mutations may be associated with a positive
immunohistochemical (IHC) staining for the MSH6 protein, which
makes them even more difficult to interpret. In the mutation
database, 12 MSH6 amino-acid substitutions are listed as
pathogenic mutations, while 16 nucleotide changes in the MSH6
coding sequence are listed as polymorphisms. In both groups some
changes are found to segregate in putative HNPCC families, while
others occur in single endometrial cancer (EC) or colorectal cancer
(CRC) patients, which impedes segregation analysis and makes
their interpretation impossible.
To address the question, which, if any, MSH6 missense
mutations cause susceptibility to HNPCC, we previously studied
the functionality of six MSH6 variants (S144I, G566R, P1087T,
P1087R, R1095H, and L1354Q) (Kariola et al, 2002, 2003). Here, we
expanded the study by analysing five novel MSH6 missense
mutations (R128L, P623L, K728T, G881KþS, and E1193K).
Distinct from the previous cases, these mutations were derived
from a population-based study of EC and CRC patients whose
tumours showed MSI, the main hallmark of HNPCC. Our
experimental results in conjunction with the clinical characteristics
of the patients provide evidence that most MSH6 missense
mutations found in a population-based case series of patients
with MSI positive tumours are unlikely to be deleterious.
MATERIALS AND METHODS
Patient specimens
MSH6 missense mutations were derived from a project comprising
altogether 2000 colorectal and EC cases newly diagnosed in the
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ymain hospitals of the Columbus metropolitan area in central
Ohio (population 1.5 million). In total, 19% of colorectal
and 22% of endometrial tumours showed instability with at least
one of five microsatellite markers (Boland et al, 1998). Blood DNA
was studied for mutations in all patients with microsatellite
unstable tumours. The six patients chosen for this study were the
ones, in which a novel MSH6 missense mutation in the coding
region was detected, no other mutations detected by DNA
sequencing occurred in MSH6, MLH1,o rMSH2, and the clinical
significance of the change could not be evaluated based on
available evidence. All studies were approved by the Institutional
Review Boards of the Ohio State University and the University of
Helsinki.
Microsatellite instability analysis
Tumours were microdissected as described previously (Chadwick
et al, 2001) and DNA extracted from tissue that contained at least
50% tumour cells. Unaffected DNA was obtained either from a
blood sample or from microdissected endometrial tissue contain-
ing no tumour cells. For the analysis, a panel of five polymorphic
microsatellite markers (BAT25, BAT26, D2S123, D5S346, and
D17S25 or D18S69) was used.
Mutation detection
Direct exon-by-exon sequencing of MLH1, MSH2, and MSH6 was
carried out in an ABI automated sequencer as described
(Chadwick et al, 2001). In MSH6, all the exons with the exception
of one part of exon 4 were sequenced in a single PCR reaction (Wu
et al, 1999).
Population frequency of missense changes
All five missense changes were searched for by SSCP using primers
and conditions available from the authors. All SSCP variants were
sequenced. The control population consisted of 140 individuals of
mixed European ethnicity including 40 grandparents from the
Centre d’Etude du Polymorphisme Humain collection obtained
from the Coriell Institute, New Jersey.
Immunohistochemical analysis
Paraffin embedded tissue was cut into 4mM sections and placed on
positively charged slides. The slides were placed in a 601C oven for
1h, cooled, and deparaffinised and rehydrated through xylenes
and graded ethanol solutions to water. All slides were quenched for
5min in a 3% hydrogen peroxide solution in methanol to block for
endogenous peroxidase. Antigen retrieval was performed by a heat
method for all three antibodies, in which the specimens were
placed in a citric acid solution (Dako’s Target Retrieval Solution,
pH 6.1), for 30min at 941C using a vegetable steamer. After
allowing slides to cool for 15min at room temperature, slides were
placed on a Dako Autostainer immunostaining system, for use
with immunhistochemistry. The primary antibody was incubated
for 1h at room temperature. The primary antibodies used were
MLH1, clone G168-728 (BD PharMingen) 1/60; MSH2, Ab-2
(Oncogene Research Products) 1/200; and MSH6 (Transduction
Laboratories) 1/400. The detection system used for all antibodies
was a labelled Streptavidin–Biotin complex. This method is based
on the consecutive application of (1) a primary antibody against
the antigen to be localised, (2) biotinylated linking antibody, (3)
enzyme conjugated streptavidin, and (4) substrate chromogen
(DAB). The tissue was protein blocked using Dako’s serum free
protein block prior to the primary antibody application. En-
dogenous avidin and biotin were blocked prior to the biotinylated-
linking antibody. Slides were then counterstained in Richard Allen
hematoxylin, dehydrated through graded ethanol solutions and
coverslipped.
MLH1 methylation analysis
Two sections of the MLH1 promoter region were studied for
methylation. Methylation-specific PCR was used to assess a region
approximately 700bp upstream of the translation initiation site
(Herman et al, 1998), designated H in this report. A combination
of bisulphite PCR and cleavage by restriction enzyme digestion
was used to study a second region that lies immediately upstream
of the translational start site (Deng et al, 1999) and designated D in
this report. The methods have been described in detail previously
(Nakagawa et al, 2001).
Site-directed mutagenesis and production of recombinant
proteins in insect cells
Site-directed mutagenesis was used to introduce the mutations
into MSH6 cDNA, which was cloned into the plasmid pFastBac1
(Gibco BRL), as described previously (Kariola et al, 2002, 2003).
The primer sequences, PCR product sizes, and cloning sites are
listed in Table 2. The mutated cloned fragments were verified by
DNA sequencing (AbiPrism 3100 Genetic Analyzer, Applied
Biosystems). The recombinant baculoviruses, which were used as
expression vectors, were generated using the Bac-to-Bac system
according to the manufacturer ´s instructions (Gibco BRL). For
protein production, Sf9 insect cells were co-transfected with MSH2
and MSH6 recombinant baculoviruses in combinations of wild-
type MSH2 (MSH2-WT) with mutated MSH6 (MSH6-R128L,
MSH6-P623L, MSH6-K728T, MSH6-G881KþS, or MSH6-E1193K)
or with wild-type MSH6 (MSH6-WT). The co-transfection was used
since both in vivo studies in mice (de Wind et al, 1999) and in vitro
studies in human cells (Marra et al, 1998; Chang et al, 2000) have
shown that the MSH6 protein (Msh6 in the mouse) is unstable in
the absence of its partner MSH2 (Msh2). After 72h of culture, the
total protein extracts (TE), including the overexpressed MSH6 and
MSH2 proteins, were prepared as described previously (Nystro ¨m-
Lahti et al, 2002).
Combined co-immunoprecipitation and Western blot
analysis
The combined co-immunoprecipitation and Western blot analysis
was performed according to previous reports (Kariola et al, 2002,
2003). The total protein extracts, which were estimated to contain
equal quantities of recombinant wild-type MSH2 protein and the
immunoprecipitated samples obtained with anti-MSH6 monoclo-
nal antibody (clone 44, BD Transduction Laboratories), were
loaded on 7.5% SDS–polyacrylamide gels. After electrophoresis,
the proteins were transferred onto nitrocellulose membranes
(Hybond-P PVDF, Amercham Pharmacia Biotech), which were
blotted with monoclonal antibodies against MSH6 (0.02mgml
 1,
clone 44, BD Transduction Laboratories) and MSH2 (0.3mgml
 1,
Ab-1, Oncogene Research Products).
In vitro MMR assay
The functionality of the recombinant MutSa (MSH2/MSH6)
variants was studied in the in vitro MMR assay (Kariola et al,
2002, 2003). In the assay, circular DNA heteroduplexes, which
contain a GKT mispair 369 base pairs downstream from a single-
strand nick were used as substrates. The functionality of the
mutated MSH6 proteins was studied by complementing MMR-
deficient nuclear extract (NE) of HCT15 (MSH6
 / ) cells with the
total protein extract (TE) of Sf9 cells including over expressed
human MSH6 and MSH2 proteins. Each protein extract was
estimated to contain equal quantities of recombinant wild-type
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complemented with wild-type MutSa TE, were used as positive
controls and HCT15 NE as a negative control in the assay. If the
repair reaction occurs, it converts GKT heteroduplex to AKT
homoduplex, whereafter restriction enzyme BglII can cleave the
molecule and the repair efficiency can be measured by the cleavage
efficiency. The quantification of the repaired DNA was carried out
with Image-Pro Version 4.0 (MediaCybernetics
s). Since the
heteroduplex molecules are not all repairable they are always
added in excess in the assay, and the repair capacity of the
proficient wild-type controls is used as a reference level.
RESULTS
Genetic and clinical data in MSH6 mutation carriers
Five novel MSH6 missense mutations (MSH6-R128L, MSH6-P623L,
MSH6-K728T, MSH6-G881KþS, MSH6-E1193K) were found in six
patients, whose endometrial or colorectal tumour showed high
MSI (when at least two out of five markers showed instability). In
each case, mutations detectable by DNA sequencing had been
excluded in MLH1 and MSH2. Furthermore, the missense changes
had not been found in 140 control individuals of comparable
ethnicity. The ages at diagnosis were high, with a range of 58–83
years, and none of the mutation carriers had first-degree relatives
with EC or CRC. The identified mutations and molecular and
clinical data are shown in Table 1.
IHC staining for MLH1, MSH2, and MSH6 revealed that MSH6
protein was lost or nearly lost (5%) in three ECs, derived from the
patient carrying the mutation P623L and the two women both
carrying the mutation E1193K. One of the latter tumours also
lacked MSH2 protein, while MLH1 was expressed. MLH1 protein
was absent in three tumours (R128L, K728T, G881KþS), in which
MSH2 and MSH6 were expressed. The lack of MLH1 in these
tumours was consistent with the finding that the same tumours
also showed hypermethylation of the MLH1 promoter region,
which often leads to MLH1 gene inactivation and loss of MMR
function.
Interactions of the MSH6 variants with wild-type MSH2
Combined co-immunoprecipitation and Western blot analysis was
used to study the effect of MSH6 mutations on the heterodimer-
isation of MSH6 and MSH2 proteins. Wild-type MutSa (MutSa-
WT) was used as a control. As shown in Figure 1A, the total
protein extracts from Sf9 cells used for immunoprecipitation assay
contained similar amounts of wild-type MSH2 (MutSa-WT,
MutSa-R128L, MutSa-P623L, MutSa-K728T, MutSa-G881KþS,
and MutSa-E1193K). The immunoprecipitates obtained with
anti-MSH6 antibody show that co-expression of four of the
MSH6 variants (MSH6-R128L, MSH6-P623L, MSH6-K728T, and
MSH6-G881KþS) with wild-type MSH2 yielded stable hetero-
dimers, since the mutated MSH6 co-precipitated similar amount of
MSH2 as wild-type MSH6. In contrast, MSH6-E1193K co-
precipitated much less MSH2 than MSH6-WT, suggesting inter-
ference in their heterodimerisation.
Mismatch repair capacity of MutSa heterodimers
The functionality of the MutSa variants was tested in an in vitro
MMR assay (Figure 1B). MutSa-WT, MutSa-R128L, MutSa-P623L,
MutSa-K728T, and MutSa-G881KþS were able to complement the
MSH6-deficient NE of HCT15 cells and repaired 39, 41, 39, 41, and
41% of GKT heteroduplexes, respectively. However, MutSa-
E1193K protein complex failed to complement HCT15 NE and
displayed complete MMR deficiency (0%).
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Genetic counselling of mutation carriers must be based on a
reliable assessment of the pathogenicity of the mutation. The
present study was undertaken to evaluate the pathogenicity of
inherited missense alterations in the MMR gene MSH6. To date,
MSH6 gene is the third most common susceptibility gene in the
HNPCC syndrome accounting for about 10% of reported muta-
tions found in HNPCC kindreds (http://www.nfdht.nl). Missense
mutations, which account for 38% of all MSH6 mutations, are
particularly challenging in the clinical management of patients
with suspected HNPCC. Even when the amino-acid substitution is
pathogenic, the mutation does not necessarily lead to the absence
of the protein; thus, it can be detectable by IHC analysis.
Furthermore, segregation studies to distinguish pathogenic muta-
tions from polymorphisms are frequently hindered by small family
size.
We have previously studied the functionality of six MSH6
variants (S144I, G566R, P1087T, P1087R, R1095H, and L1354Q),
four of which are listed as pathogenic mutations in the mutation
database. The mutations were found in HNPCC kindreds, which
did not fulfil the Amsterdam criteria (I or II) and were classified as
non-HNPCC or suspected HNPCC families (Vasen et al, 1991,
1999). The same functional assay was previously used to detect
impaired MMR caused by the MLH1 missense mutations C77R,
I107R, and R659P (Nystro ¨m-Lahti et al, 2002). Interestingly, all the
six mutated MSH6 proteins were able to repair mismatches
(Kariola et al, 2002, 2003), suggesting no MMR defect detectable in
our assay. To further address the question of whether MSH6
missense mutations cause MMR defect and susceptibility to
HNPCC, the pathogenicity of five novel MSH6 missense variations
(R128L, P623L, K728T, G881KþS, and E1193K) was evaluated in
the present study. These changes were derived from a series of
consecutive EC and CRC patients selected for study after their
tumours were determined to be microsatellite unstable. Impor-
tantly, in each case, the mutation was searched for in 140 control
individuals and not found. Thus, these changes could not be
classified a priori as likely polymorphisms. Irrespective of these
facts, none of the mutation carriers was shown to have first-degree
relatives with EC or CRC or any family history of cancer suggestive
of HNPCC.
We studied the interactions of five mutated MSH6 proteins with
normal MSH2 and tested the functionality of these heterodimers of
MSH6 and MSH2 in the in vitro MMR assay. Four mutations
(R128L, P623L, K728t, G881KþS) showed no impairment of these
functions while the fifth mutation (E1193K) displayed marked
impairment of both functions. The MSH6-E1193K protein co-
precipitated much less MSH2 than wild-type MSH6, and the
heterodimer MutSa-E1193K could not repair mismatches. The
E1193K mutation occurred in two independently ascertained
women with EC (ages at onset 59 and 60 years). Both tumours
stained negatively or very weakly for MSH6 protein, which is
compatible with MMR deficiency associated with MSH6 mutation.
The amino acid E1193 is located in a highly conserved region
between the ATP and Mg
2þ binding sites in MSH6 (Iaccarino et al,
1998, 2000; Dufner et al, 2000) and, accordingly, can be expected to
be sensitive to alterations. Irrespective of the definite MMR
deficiency associated with the E1193K mutation, the families of the
two patients, their siblings, excluding one brother diagnosed with
skin cancer at 60, parents and children were unaffected. In
immunohistochemical analysis, the three tumours derived from
patients carrying mutations R128L, K728T, and G881KþS,
expressed MSH6 but lacked MLH1 protein, which may explain
the MSI phenotype in these tumours and suggests IHC staining for
the MLH1 protein as the first approach in microsatellite unstable
tumours. However, the mutation, P623L, which had no detectable
phenotype in our functional assay was found in a patient, whose
EC showed high MSI, and MSH6 was the only nonexpressed
protein in the tumour among the three proteins tested. Thus, we
cannot exclude the possibility that pathogenicity of P623L is
caused by lower levels of the functional MSH6 protein as we have
previously shown to be the case with some MLH1 mutations
(Raevaara et al, 2003). Another possibility is that MSH6
inactivation is not at all due to P623L but has been acquired as a
somatic event during the development of the tumour.
Our results, taken together with our previous similar findings
concerning six other missense mutations in MSH6 and the clinical
data of the patients and their families, lead us to conclude that
most missense changes in MSH6 cause no or low cancer
susceptibility. The results do not exclude the possibility that some
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Figure 1 (A) Combined immunoprecipitation and Western blot analysis
showing interactions of MSH6 variants with wild-type MSH2. The upper
panel shows a Western blot including total protein extracts (TE), the lower
panel shows immunoprecipitates (IP) obtained with anti-MSH6 antibody.
Following transfer onto the membrane, the proteins were visualised with
anti-MSH6 and anti-MSH2 antibodies (see Materials and Methods). The
figure shows that the mutated MSH6 proteins R128L, P623L, K728T, and
G881KþS are able to form stable MSH2-MSH6 heterodimers and co-
precipitate a similar amount of the MSH2 protein as wild-type MSH6, while
MSH6-E1193K co-precipitates clearly less MSH2 protein. (B) MMR activity
of MMR deficient nuclear extract of HCT15 cells complemented with wild-
type MutSa (MutSa-WT) and mutated variants. Mock contains hetero-
duplex DNA with no protein, TK6 is an MMR-proficient and HCT15 an
MMR-deficient (MSH6
 / ) control (see Materials and Methods). The
fragment lengths on the left indicate the migration of the unrepaired
linearised plasmid DNA (3193bp) and of the two fragments (1833 and
1360bp) produced following correction of the GKT mispair, which makes
the DNA susceptible to cleavage with the restriction endonuclease BglII.
The numbers below the panel represent fractions (%) of repaired DNA
and display absolute MMR deficiency (0%) of MutSa-E1193K. The values
are an average of two independent experiments.
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vitro MMR assay, could still affect biochemical events preceding
the MMR function in vivo. Yet, a functional MMR defect, especially
in situations where cosegregation of missense mutation and
disease phenotype cannot be studied, reliably confirms that cancer
susceptibility in a family is linked to a found mutation.
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